<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04897672</url>
  </required_header>
  <id_info>
    <org_study_id>RECHMPL21_0344</org_study_id>
    <nct_id>NCT04897672</nct_id>
  </id_info>
  <brief_title>2D-speckle Tracking in Pediatric Renal Chronic Disease</brief_title>
  <acronym>SPECKLEKIDNEY</acronym>
  <official_title>Use of 2D-Speckle Tracking Echocardiography in a Pediatric Population With Chronic Renal Disease: a Multicentre Cross-sectional Controlled Study (SPECKLE-KIDNEY-PED)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Montpellier</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Toulouse University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Bordeaux</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Limoges</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Marseille University Hospital- La Timone</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>AP-HP - Hopital Robert Debr√©</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Montpellier</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The SPECKLE- KIDNEY-PED is a multicentre observational controlled trial aiming to evaluate&#xD;
      the 2D-Speckle tracking in a population of 85 patients aged from 6 to 17 years old with a&#xD;
      chronic renal disease and to compare the results to those of 85 age and gender-matched&#xD;
      healthy subjects. The secondary objective is to assess the conventional echocardiographic&#xD;
      parameters and the level of exercice capacity.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Kidney disease and chronic kidney failure are one of the most common causes of chronic&#xD;
      childhood disease. They are often complicated by cardiovascular disease, which can, in the&#xD;
      long run, affect patients' prognosis. Thus, mortality in children undergoing hemodialysis for&#xD;
      end-stage kidney failure is related in more than 30% of cases to a cardiovascular&#xD;
      complication. An annual cardiac assessment is recommended as part of the follow-up of these&#xD;
      patients to assess the cardiac impact of kidney disease (high blood pressure, hyper-uremia,&#xD;
      etc.). The use of conventional cardiological assessment parameters does not predict the&#xD;
      cardiovascular prognosis of patients because the alteration of these parameters is greatly&#xD;
      delayed in the course of the disease. 2D strain or &quot;speckle tracking echocardiography&quot; is a&#xD;
      non-invasive ultrasound technique that allows for a more sensitive assessment of myocardial&#xD;
      tissue damage and its early impairment has been shown as a factor of poor prognosis in other&#xD;
      pediatric chronic pathology (neuromuscular disease, cardiotoxic exposure, etc.) as well as in&#xD;
      adult chronic kidney failure.&#xD;
&#xD;
      The SPECKLE- KIDNEY-PED trial is a multicentre observationnal controlled study. The main&#xD;
      objective of this work is to asses the 2D strain ventricular function in children with kidney&#xD;
      failure, to compare it with that of healthy children of 6 to 17 years old, and to correlate&#xD;
      it with the cardio-renal severity of the disease in terms of level of kidney failure and&#xD;
      aerobic physical fitness.&#xD;
&#xD;
      The secondary objective is to assess, in this population, the level of exercice capacity and&#xD;
      to compare it to the general population of children of the same age.&#xD;
&#xD;
      A total of 180 children are recquired to observe a significant difference of 2,5% of the&#xD;
      global strain value with a power of 90% and an alpha risk of 5%.&#xD;
&#xD;
      The SPECKLE- KIDNEY-PED trial intends to improve the level of evidence for future guidelines&#xD;
      on cardiologic survey and promotion of physical activity in this population&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 1, 2021</start_date>
  <completion_date type="Anticipated">December 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Global and segmentary longitudinal 2D- speckle tracking value of the left ventricule by transthoracic echocardiography</measure>
    <time_frame>Baseline (1day)</time_frame>
    <description>Transthoracic echocardiography parameters</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Conventional echocardiography parameters</measure>
    <time_frame>Baseline (1day)</time_frame>
    <description>ransthoracic echocardiography parameters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exercice capacity</measure>
    <time_frame>Baseline (1day)</time_frame>
    <description>Cardiopulmonary exercice test with VO2max assessment</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">170</enrollment>
  <condition>Chronic Renal Disease</condition>
  <condition>Chronic Renal Insufficiency</condition>
  <condition>Congenital Heart Disease</condition>
  <arm_group>
    <arm_group_label>case</arm_group_label>
    <description>case: Children aged 6 to 17 years old reffered to the pediatric cardiology consultation with a chronic renal disease and renal insufficiency</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control</arm_group_label>
    <description>control : Children aged 6 to 17 years old reffered to the pediatric cardiology consultation who were classified in the control group after a completely normal check-up, including physical examination, electrocardiogram, and echocardiography</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Observational study</intervention_name>
    <description>Observational study</description>
    <arm_group_label>case</arm_group_label>
    <arm_group_label>control</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Cases group : Children aged 6 to 17years old with chronic renal insufficiency&#xD;
&#xD;
        Control group: Children aged 6 to 17 years old with normal check up&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Patient aged 6 to 17 years old&#xD;
&#xD;
          -  Patient with chronic renal disease (&gt;3 months)&#xD;
&#xD;
          -  Patient with renal insufficiency (glomerular filtration rate &lt; 80ml/min/1,73m2)&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Patient with associated congenital heart disease&#xD;
&#xD;
          -  Patient with uncontrolled arrythmia&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pascal AMEDRO, MD-PhD</last_name>
    <role>Study Director</role>
    <affiliation>UH MONTPELLIER</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Oscar WERNER, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UH MONTPELLIER</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pascal AMEDRO, MD-PhD</last_name>
    <phone>04 67 33 66 43</phone>
    <email>p-amedro@chu-montpellier.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Oscar WERNER, MD</last_name>
    <phone>467336632</phone>
    <phone_ext>33</phone_ext>
    <email>o-werner@chu-montpellier.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Uh Montpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pascal AMEDRO, MD-PHD</last_name>
      <phone>467336643</phone>
      <phone_ext>33</phone_ext>
      <email>p-amedro@chu-montpellier.fr</email>
    </contact>
    <contact_backup>
      <last_name>Oscar WERNER, MD</last_name>
      <phone>4 67 33 66 32</phone>
      <phone_ext>33</phone_ext>
      <email>o-werner@chu-montpellier.fr</email>
    </contact_backup>
    <investigator>
      <last_name>MORIN</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>FILA</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>DECRAMER</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>DULAC</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>ACAR</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>HARAMBAT</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>IRIART</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>THAMBO</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>GUIGONIS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>BROSSET</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>TSIMARATOS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>OVAERT</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>HOGAN</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>BEYLER</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 18, 2021</study_first_submitted>
  <study_first_submitted_qc>May 18, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 21, 2021</study_first_posted>
  <last_update_submitted>May 25, 2021</last_update_submitted>
  <last_update_submitted_qc>May 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Speckle-tracking</keyword>
  <keyword>Exercice capacity</keyword>
  <keyword>Cardiovascular prognosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Heart Defects, Congenital</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>NC</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

